Plague tolerance has always been a major research difficulty and goal.
A few months ago, the journal Stem Cells Translational Medicine reported the case of an Italian kidney transplant recipient who received an autologous Mesenchymal Stem cell infusion to induce immune tolerance, the new organ was completely tolerated for 18 months after the immunosuppressive drug was gradually reduced to withdrawal. The study reported a 37-year-old man with IgA nephropathy, who developed end-stage renal disease and received a living donor kidney transplant in October 2010, he also participated in a pilot study on the safety and feasibility of infusion of ex vivo-amplified autologous bone marrow Mesenchymal stem cell before transplantation. The day before the transplant, the patient received an autologous bone marrow Mesenchymal stem cell infusion and was treated with a low-dose intravenous infusion of rabbit anti-human thymocyte immunoglobulin for six days after the transplant. The patient’s kidney function recovered and remained stable after transplantation. Renal biopsy showed no evidence of clinical rejection. The amount of immunosuppressant the patient was taking was gradually reduced until he or she stopped taking it altogether. At the time of reporting, the patient had been off immunosuppressants for 18 months and had normal renal function.
This study provides evidence of the effectiveness of Mesenchymal stem cell in solving the problem of organ rejection in living donor kidney transplantation, autologous bone marrow Mesenchymal stem cell is associated with posttransplant safety, complete immunosuppressive drug withdrawal, and eventual immune tolerance, providing new insight into the underlying mechanisms. Although the study was limited to a single patient, the investigators are confident that the phenomenon observed in this case after transplantation can be attributed to the continued tolerability environment promoted by Mesenchymal stem cell therapy. The injected Mesenchymal stem cell may have long-term immunosuppressivetolerant activity, possibly through the release of extracellular vesicles, which are maintained after Mesenchymal stem cell.
A large number of basic experimental studies have confirmed that Mesenchymal stem cell has a significant effect on the regulation of immune cell function, which has laid a good theoretical foundation for the treatment of organ transplantation rejection with Mesenchymal stem cell. It is believed that the application of Mesenchymal stem cell therapy in the field of transplantation will be mature in the future.
Notice: the survey on the importance of immunosuppressant compliance in renal transplant patients is still underway. We welcome your active participation. If you have any questions about immunosuppressant, you can leave a comment at the end of the questionnaire, and we’ll reply to you in the form of tweets from time to time.
Click on the picture, scan the QR code below, you can participate in the survey, thank you for your cooperation ~
References
Casiraghi F, Perico N, Gotti E, et al. Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration[J]. STEM CELLS Translational Medicine,2020,9(4):427-432
Article | Zhuo ran, illustrations | Zou Juan
This article is an original article of”Kidney Transplantation, sun yat-sen hospital, Fudan University”. It is reproduced with the author’s permission and marked with the source. Care about the kidney, from the concern”Fudan University affiliated Zhongshan Hospital Kidney Transplant” public wechat start, you can also click [ read the original ] , view大豆及其制品，肾友们真的知道该如何吃吗？
